Phytochemicals in Alzheimer disease: The development of clinical trials

被引:5
|
作者
Quinn, J
Kaye, J
Montine, T
Stackman, R
机构
[1] Portland VA Med Ctr, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA
[3] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
关键词
Alzheimer disease; antioxidants; oxidative stress; polyphenolics;
D O I
10.3109/138802090893531
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that. are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.
引用
收藏
页码:64 / 73
页数:10
相关论文
共 50 条
  • [31] Drug candidates in clinical trials for Alzheimer’s disease
    Shih-Ya Hung
    Wen-Mei Fu
    Journal of Biomedical Science, 24
  • [32] BACE Inhibitor Clinical Trials for Alzheimer's Disease
    Watkins, Elyse A.
    Vassar, Robert
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S41 - S52
  • [33] Alzheimer’s Disease Clinical Trials: Changing the Paradigm
    Jeffrey L. Cummings
    Current Psychiatry Reports, 2011, 13 : 437 - 442
  • [34] Placebos in clinical trials in Alzheimer disease: An international discussion
    Whitehouse, PJ
    Arizaga, R
    Brodaty, H
    Gauthier, S
    Graham, N
    Green, RC
    Homma, A
    Mangone, C
    Senanarong, V
    Xu, XH
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1999, 13 (03): : 121 - 123
  • [35] Power Calculations for Clinical Trials in Alzheimer's Disease
    Ard, M. Colin
    Edland, Steven D.
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 26 : 369 - 377
  • [36] Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease
    Elghanam, Yomna
    Purja, Sujata
    Kim, Eun Young
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 99 (02) : 693 - 703
  • [37] Neuroimaging outcomes in clinical trials in Alzheimer’s disease
    Giovanni B. Frisoni
    A. Delacourte
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 209 - 212
  • [38] Mixed Dementia in Clinical Trials of Alzheimer's Disease
    Massoud, Fadi
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2012, 39 (05) : 566 - 567
  • [39] Alzheimer's Disease Clinical Trials: Changing the Paradigm
    Cummings, Jeffrey L.
    CURRENT PSYCHIATRY REPORTS, 2011, 13 (06) : 437 - 442
  • [40] Clinical trials in Alzheimer's disease: a congress of prevention
    Ousset, P. J.
    CAHIERS DE L ANNEE GERONTOLOGIQUE, 2010, 2 (01): : 67 - 67